Biotech & Pharmaceuticals

Meg Tirrell reports from the American Society of Hematology’s annual meeting where many of the latest blood disease treatments were presented.

There may be a big advantage to treating people with personalized medicine — drugs and treatments tailored to an individual’s genetic profile — but improved health outcomes for them will come at a big cost. That’s because it is very costly to screen patients for such tailored treatments and to produce medicine that targets individuals …

Of the 41 new drugs that were FDA-approved in 2014, 18 were for drugs with orphan indications, a record level.

Pfizer and Allergan are combining in a $160 billion deal, handing Pfizer a new address and creating a lot of controversy.

Over the next couple of weeks two drugs that combat a rare and fatal form of muscular dystrophy will come under review, in what could be a watershed moment for patients.

Why one lawsuit accuses a drug company of illegally driving sales of its pain killing drug.

Insys Therapeutics CEO Michael Babich has stepped down, with company chairman Dr. John Kapoor taking over as CEO. The news comes as the company reported third quarter earnings on Thursday, and shortly after CNBC released an investigative piece on Wednesday on the company, which included allegations of fraud, kickbacks, and aggressive drug marketing behavior by …

The United States’ opiate drug problem isn’t limited to illegal narcotics. The sale of dangerously addictive painkillers willfully prescribed by our physicians has quadrupled in the past decade, and one company in particular is pushing pain to the legal edge of aggressive medical marketing. According to criminal complaints, attorney generals’ reports and CNBC sources, specialty …

Valeant cuts ties with specialty pharmacy Philidor, which distributed some of its prescriptions.

Pfizer and Allergan are in merger talks that could create the world’s largest pharmaceutical company.

Ireland-based Allergan on Thursday confirmed that it has been approached by Pfizer and is in talks regarding a potential deal with the U.S. drug company, raising questions about another pharmaceutical tax inversion. Allergan said no agreement had been reached, describing the talks as “preliminary and friendly.” Shares of Allergan popped about 9 percent in early …

What the big merger between Walgreens Boots Alliance and Rite Aid could mean for you.

Shares of Eli Lilly slide after it scrapped an experimental cholesterol drug that was once thought to have big potential.

Express Scripts, the largest pharmacy benefits manager in the U.S., says it’s got a plan to fight drug price increases: Refuse to pay. “We actually have inflation protection, which is really important,” Express Scripts Chief Medical Officer Dr. Steve Miller said in a telephone interview Tuesday. “What really frustrates employers and other plan sponsors is …

Seniors, get ready to dig deeper into your wallets, or to start shopping more. More than 15 million people enrolled in the top 10 Medicare “Part D” prescription drug plans will face average premium hikes of 8 percent next year, according to a new analysis. Those top 10 plans account for more than 80 percent …